- Home
- IVP vs AZTR Comparison
IVP vs AZTR Comparison
Compare IVP & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- AZTR
- Stock Information
- Founded
- IVP 2020
- AZTR 2014
- Country
- IVP United States
- AZTR United States
- Employees
- IVP N/A
- AZTR N/A
- Industry
- IVP Diversified Commercial Services
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- AZTR Health Care
- Exchange
- IVP Nasdaq
- AZTR Nasdaq
- Market Cap
- IVP 3.5M
- AZTR 4.2M
- IPO Year
- IVP 2023
- AZTR 2023
- Fundamental
- Price
- IVP $0.88
- AZTR $0.58
- Analyst Decision
- IVP
- AZTR Strong Buy
- Analyst Count
- IVP 0
- AZTR 1
- Target Price
- IVP N/A
- AZTR $4.00
- AVG Volume (30 Days)
- IVP 123.8K
- AZTR 5.2M
- Earning Date
- IVP 11-12-2025
- AZTR 11-11-2025
- Dividend Yield
- IVP N/A
- AZTR N/A
- EPS Growth
- IVP N/A
- AZTR N/A
- EPS
- IVP N/A
- AZTR N/A
- Revenue
- IVP $15,292,904.00
- AZTR N/A
- Revenue This Year
- IVP N/A
- AZTR N/A
- Revenue Next Year
- IVP N/A
- AZTR N/A
- P/E Ratio
- IVP N/A
- AZTR N/A
- Revenue Growth
- IVP N/A
- AZTR N/A
- 52 Week Low
- IVP $0.63
- AZTR $0.50
- 52 Week High
- IVP $8.00
- AZTR $4.33
- Technical
- Relative Strength Index (RSI)
- IVP 40.92
- AZTR 39.69
- Support Level
- IVP $0.85
- AZTR $0.50
- Resistance Level
- IVP $1.01
- AZTR $1.09
- Average True Range (ATR)
- IVP 0.05
- AZTR 0.08
- MACD
- IVP -0.01
- AZTR -0.02
- Stochastic Oscillator
- IVP 19.44
- AZTR 12.85
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.